Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis
Antimicrob Agents Chemother. 2024 May 1:e0012424. doi: 10.1128/aac.00124-24. Online ahead of print.ABSTRACTAs an obligate aerobe, Mycobacterium tuberculosis relies on its branched electron transport chain (ETC) for energy production through oxidative phosphorylation. Regimens targeting ETC exhibit promising potential to enhance bactericidal activity against M. tuberculosis and hold the prospect of shortening treatment duration. Our previous research demonstrated that the bacteriostatic drug candidate TB47 (T) inhibited the growth of M. tuberculosis by targeting the cytochrome bc1 complex and exhibited synergistic activity ...
Source: Antimicrobial Agents and Chemotherapy - May 1, 2024 Category: Microbiology Authors: Wei Yu Yanan Ju Xingli Han Xirong Tian Jie Ding Shuai Wang H M Adnan Hameed Yamin Gao Lei Li Yongguo Li Nanshan Zhong Tianyu Zhang Source Type: research
A pairwise approach to revitalize β-lactams for the treatment of TB
Antimicrob Agents Chemother. 2024 May 1:e0003424. doi: 10.1128/aac.00034-24. Online ahead of print.ABSTRACTThe dual β-lactam approach has been successfully applied to overcome target redundancy in nontuberculous mycobacteria. Surprisingly, this approach has not been leveraged for Mycobacterium tuberculosis, despite the high conservation of peptidoglycan synthesis. Through a comprehensive screen of oral β-lactam pairs, we have discovered that cefuroxime strongly potentiates the bactericidal activity of tebipenem and sulopenem-advanced clinical candidates-and amoxicillin, at concentrations achieved clinically. β-lactam pa...
Source: Antimicrobial Agents and Chemotherapy - May 1, 2024 Category: Microbiology Authors: Dereje A Negatu Wassihun Wedajo Aragaw V éronique Dartois Thomas Dick Source Type: research
The Spx stress regulator confers high-level β-lactam resistance and decreases susceptibility to last-line antibiotics in methicillin-resistant < em > Staphylococcus aureus < /em >
Antimicrob Agents Chemother. 2024 May 1:e0033524. doi: 10.1128/aac.00335-24. Online ahead of print.ABSTRACTInfections caused by methicillin-resistant Staphylococcus aureus (MRSA) are a leading cause of mortality worldwide. MRSA has acquired resistance to next-generation β-lactam antibiotics through the horizontal acquisition of the mecA resistance gene. Development of high resistance is, however, often associated with additional mutations in a set of chromosomal core genes, known as potentiators, which, through poorly described mechanisms, enhance resistance. The yjbH gene was recently identified as a hot spot for adaptiv...
Source: Antimicrobial Agents and Chemotherapy - May 1, 2024 Category: Microbiology Authors: Tobias Krogh Nielsen Ida Birkj ær Petersen Lijuan Xu Maria Disen Barbuti Viktor Mebus Anni Justh Abdulelah Ahmed Alqarzaee Nicolas Jacques C écile Oury Vinai Thomas Morten Kjos Camilla Henriksen Dorte Frees Source Type: research
Determinants of Symptomatic Intracranial Progression After an Initial Stereotactic Radiosurgery Course
CONCLUSIONS: In this cohort study of patients with brain metastases completing SRS, neurologic symptoms at ITCP is prognostic for OS. This data informs post-SRS surveillance in clinical practice as well as future prospective studies needed in the modern management of brain metastases.PMID:38690297 | PMC:PMC11059392 | DOI:10.1016/j.adro.2024.101475 (Source: Adv Data)
Source: Adv Data - May 1, 2024 Category: Epidemiology Authors: Jim X Leng David J Carpenter Christina Huang Jamiluddin Qazi Muzamil Arshad Trey C Mullikin Zachary J Reitman John P Kirkpatrick Scott R Floyd Peter E Fecci Steven J Chmura Julian C Hong Joseph K Salama Source Type: research
Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept
World J Hepatol. 2024 Apr 27;16(4):490-493. doi: 10.4254/wjh.v16.i4.490.ABSTRACTCancer immunotherapy is administered for first-line, second-line, neoadjuvant, or adjuvant treatment of advanced, metastatic, and recurrent cancer in the liver, gastrointestinal tract, and genitourinary tract, and other solid tumors. Erdafitinib is a fibroblast growth factor receptor (FGFR) inhibitor, and it is an adenosine triphosphate competitive inhibitor of FGFR1, FGFR2, FGFR3, and FGFR4. Immune checkpoint inhibitors are monoclonal antibodies that block programmed cell death protein 1 (PD-1) and its ligand that exert intrinsic antitumor mec...
Source: World Journal of Hepatology - May 1, 2024 Category: Gastroenterology Authors: Mohamed Wishahi Source Type: research
Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center
Conclusion: First in oncology, OOM was applied, which found some other significant characteristics associated with RS than traditional statistical methods. There were few patients, where no clinical associations were found between characteristics and RS contrary to statistically significant differences. Therefore, the results of these statistical analyses can be neither applied for individual cases nor able to provide the bases for screening patients, i.e., whether they need for OncotypeDX testing or not. OncotypeDX still provides a personalised approach in BC.PMID:38689824 | PMC:PMC11058978 | DOI:10.3389/pore.2024.1611735...
Source: Pathology Oncology Research - May 1, 2024 Category: Pathology Authors: D ániel Deme B álint Ferenc Tamaskovics Nizar Jammoul S ándor Kovács Emmanuel Oladunjoye Kayode James W Grice Andr ás Telekes Source Type: research
Drug-induced mucosal alterations observed during esophagogastroduodenoscopy
World J Gastroenterol. 2024 Apr 28;30(16):2220-2232. doi: 10.3748/wjg.v30.i16.2220.ABSTRACTSeveral features of drug-induced mucosal alterations have been observed in the upper gastrointestinal tract, i.e., the esophagus, stomach, and duodenum. These include pill-induced esophagitis, desquamative esophagitis, worsening of gastroesophageal reflux, chemotherapy-induced esophagitis, proton pump inhibitor-induced gastric mucosal changes, medication-induced gastric erosions and ulcers, pseudomelanosis of the stomach, olmesartan-related gastric mucosal inflammation, lanthanum deposition in the stomach, zinc acetate hydrate tablet...
Source: World Journal of Gastroenterology - May 1, 2024 Category: Gastroenterology Authors: Masaya Iwamuro Seiji Kawano Motoyuki Otsuka Source Type: research
A novel mitochondrial unfolded protein response-related risk signature to predict prognosis, immunotherapy and sorafenib sensitivity in hepatocellular carcinoma
AbstractHepatocellular carcinoma (HCC) is a common cause of cancer-associated death worldwide. The mitochondrial unfolded protein response (UPRmt) not only maintains mitochondrial integrity but also regulates cancer progression and drug resistance. However, no study has used the UPRmt to construct a prognostic signature for HCC. This work aimed to establish a novel signature for predicting patient prognosis, immune cell infiltration, immunotherapy, and chemotherapy response based on UPRmt-related genes (MRGs). Transcriptional profiles and clinical information were obtained from the TCGA and ICGC databases. Cox regression a...
Source: Apoptosis - May 1, 2024 Category: Molecular Biology Source Type: research
PANoptosis subtypes predict prognosis and immune efficacy in gastric cancer
AbstractPANoptosis is a form of inflammatory programmed cell death that is regulated by the PANoptosome. This PANoptosis possesses key characteristics of pyroptosis, apoptosis, and necroptosis, yet cannot be fully explained by any of these cell death modes. The unique nature of this cell death mechanism has garnered significant interest. However, the specific role of PANoptosis-associated features in gastric cancer (GC) is still uncertain. Patients were categorized into different PAN subtypes based on the expression of genes related to the PANoptosome. We conducted a systematic analysis to investigate the variations in pro...
Source: Apoptosis - May 1, 2024 Category: Molecular Biology Source Type: research
FAM83B regulates mitochondrial metabolism and anti-apoptotic activity in pulmonary adenocarcinoma
This study aims to understand how increased FAM83B expression impacts mitochondrial activity, cell apoptosis, and chemotherapy effectiveness in LUAD. Multiple assays, such as CCK8, wound healing, EdU, and transwell assays, were employed to confirm the augmented chemotherapy resistance, heightened cell proliferation, migration, and invasion caused by FAM83B overexpression in LUAD cells. Furthermore, MIMP, MTG, and ATP assays were utilized to quantify changes in mitochondrial metabolism. In vitro functional assays were performed to evaluate the influence of FAM83B overexpression on the malignant progression and resistance me...
Source: Apoptosis - May 1, 2024 Category: Molecular Biology Source Type: research
Dysgerminoma with Syncytiotrophoblastic Giant Cells Associated with a Concurrent Ectopic Pregnancy
AbstractBackgroundDysgerminomas constitute around 1 –2% of all germ cell tumours. It is very very rare to have dysgerminoma with concurrent pregnancy with an incidence of 0.2–1 per 100,000 pregnancies. It is extremely difficult to conceive with no assisted reproductive interventions and carry it till completion with no complications in a concurre nt dysgerminoma. Dysgerminoma has a characteristic specific histomorphology and is easy to diagnose. However, occasionally, syncytiotrophoblastic differentiation can be seen in dysgerminoma although it is a rare histopathological finding. Also, the raised serum B-HCG levels du...
Source: Indian Journal of Surgical Oncology - May 1, 2024 Category: Cancer & Oncology Source Type: research
Evaluating the effect of a mobile-based symptom monitoring system for improving physical function in patients with cancer during chemotherapy: study protocol for a multicentre randomised controlled trial
This study is a multicentre, open-label, parallel-group, randomised controlled trial. We will recruit 372 patients at three tertiary hospitals located in Seoul, South Korea. Study participants will be randomly assigned to either an intervention group receiving the ePRO-CTCAE app and a control group receiving routine clinical practice only. The primary outcome is changes in physical function from commencement to completion of planned chemotherapy. A linear mixed model will be performed under the intention-to-treat principle. The secondary outcomes include physical activity level; changes in pain interference; changes in dep...
Source: BMJ Open - May 1, 2024 Category: General Medicine Authors: Lee, M., Kang, D., Um, Y., Jo, B., Rhue, J., Park, S., Lee, Y.-Y., Noh, J. J., Lee, Y.-G., Koo, D.-H., Park, K.-H., Lee, S., Ahn, J. S., Oh, D., Cho, J. Tags: Open access, Health services research Source Type: research
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study
ConclusionIn line with the results of the TOPAZ-1 trial, adding durvalumab to cisplatin/gemcitabine has been confirmed to confer a survival benefit in terms of OS and PFS in a real-world setting of patients with advanced BTC. (Source: Targeted Oncology)
Source: Targeted Oncology - May 1, 2024 Category: Cancer & Oncology Source Type: research
Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study
ConclusionsThis is the first administrative data-based real-world evidence on treatment sequence and outcomes for patients with early recurrence CRC treated with FOLFIRI+AAs or FOLFIRI+ anti-EGFR antibodies after adjuvant FOLFOX/CAPOX therapy in Japan. Both regimens had similar TTD, but relapse timing and tumor sidedness may influence their efficacy. (Source: Targeted Oncology)
Source: Targeted Oncology - May 1, 2024 Category: Cancer & Oncology Source Type: research
Trastuzumab and first-line taxane chemotherapy in metastatic breast cancer patients with a HER2-negative tumor and HER2-positive circulating tumor cells: a phase II trial
ConclusionNo clinical benefit of trastuzumab was observed, although this study was performed in a limited number of patients. Additionally, we observed a strong correlation between the number of evaluable CTCs and the presence of HER2-positive CTCs. We argue that randomized studies investigating agents that are proven to be solely effective in the HER2-positive patient group in patients with HER2-positive CTCs and HER2-negative tissue are currently infeasible. Several factors contribute to this impracticality, including the need for more stringent thresholds, and the rapidly evolving landscape of cancer treatments. (Source...
Source: Breast Cancer Research and Treatment - May 1, 2024 Category: Cancer & Oncology Source Type: research
